comparemela.com
Home
Live Updates
Patient Sub Groups - Breaking News
Pages:
Latest Breaking News On - Patient sub groups - Page 1 : comparemela.com
89bio Announces New Positive Long-Term Data from the ENLIVEN Phase 2b Trial of Pegozafermin in Patients with Nonalcoholic Steatohepatitis (NASH)
Data at week 48 demonstrated that treatment with pegozafermin led to sustained statistically significant improvements across liver fat and non-invasive tests of liver injury/inflammation and.
United states
San francisco
Hank mansbach
Annie chang
Sheryl seapy
Drug administration
Lifesci advisors
Exchange commission
Chief medical officer
Extension phase
Main study
Phase data
Treatment effects were robust
Patient sub groups
Lipids results
Breakthrough therapy
vimarsana © 2020. All Rights Reserved.